1
Paul R Meers, Charles Pak, Shaukat Ali, Andrew Janoff, J Craig Franklin, Ravi K Erukulla, Donna Cabral Lilly: Peptide-lipid conjugates. The Liposome Company, Rosanne Goodman, July 11, 2000: US06087325 (52 worldwide citation)

Peptide-lipid conjugates are incorporated into liposomes so as to selectively destabilize the liposomes in the vicinity of target peptidase-secreting cells, and hence, to deliver the liposomes to the vicinity of the target cells, or directly into the cells. The liposomes can thus be used to treat ma ...


2
Paul R Meers, Charles Pak, Shaukat Ali, Andrew Janoff, J Craig Franklin, Ravi K Erukulla, Donna Cabral Lilly, Patrick L Ahl: Peptide-lipid conjugates, liposomes and lipsomal drug delivery. Elan PharmaceuticalsTechnologies, Burns Doane Swecker & Mathis L, January 15, 2002: US06339069 (41 worldwide citation)

Peptide-lipid conjugates are incorporated into liposomes so as to selectively destabilize the liposomes in the vicinity of target peptidase-secreting cells, and hence, to deliver the liposomes to the vicinity of the target cells, or directly into the cells. The liposomes can thus be used to treat ma ...


3
Paul R Meers, Charles Pak, Shaukat Ali, Andrew Janoff, J Craig Franklin, Ravi K Erukulla, Donna Cabral Lilly: Liposomal peptide-lipid conjugates and delivery using same. The Liposome Company, Rosanne Goodman, November 7, 2000: US06143716 (8 worldwide citation)

Peptide-lipid conjugates are incorporated into liposomes so as to selectively destabilize the liposomes in the vicinity of target peptidase-secreting cells, and hence, to deliver the liposomes to the vicinity of the target cells, or directly into the cells. The liposomes can thus be used to treat ma ...


4
Meers Paul, Pak Charles, Ali Shaukat, Janoff Andrew, Franklin J Craig, Erukulla Ravi, Cabral Lilly Donna, Ahl Patrick: Peptide-lipid conjugates, liposomes and liposomal drug delivery. Liposome, April 24, 2002: EP1198256-A1

Peptide-lipid conjugates are incorporated into liposomes so as to selectively destabilize the liposomes in the vicinity of target peptidase-secreting cells, and hence, to deliver the liposomes to the vicinity of the target cells, or directly into the cells. The liposomes can thus be used to treat ma ...


5
Anirban Sen Gupta, Madhumitha Ravikumar, Christa Modery: Heteromultivalent particle compositions. Case Western Reserve University, Tarolli Sundheim Covell & Tummino, December 5, 2017: US09833518

A composition for use in diagnostic and therapeutic applications includes a heteromultivalent nanoparticle or microparticle having an outer surface and a plurality of targeting moieties conjugated to the surface of the nanoparticle or microparticle, the targeting moieties includes a first activated ...


6
Vit Lauermann: Method of site specific activation of an antibody by a protease. October 3, 2017: US09775913

The invention relates to molecules inhibiting biologically active compounds and further comprising moieties specifically cleavable by a reagent produced by a target cell. More specifically, the invention relates to inhibitors that bind, inhibit, suppress, neutralize, or decrease activity of a biolog ...


7
Meers Paul R, Pak Charles, Ali Shaukat, Janoff Andrew S, Franklin J Craig, Erukulla Ravi K, Cabral Lilly Donna: Peptide-lipid conjugates, liposomes and liposomal drug delivery. Liposome Co, December 22, 1999: EP0964690-A1

Peptide-lipid conjugates are incorporated into liposomes so as to selectively destabilize the liposomes in the vicinity of target peptidase-secreting cells, and hence, to deliver the liposomes to the vicinity of the target cells, or directly into the cells. The liposomes can thus be used to treat ma ...


8
Meers Paul R, Pak Charles, Ali Shaukat, Janoff Andrew S, Franklin J Craig, Erukulla Ravi K, Cabral Lilly Donna: Conjugues de peptide-lipide, liposomes et apport de medicaments par des liposomes, Peptide-lipid conjugates, liposomes and liposomal drug delivery. The Liposome Company, Transave, Osler Hoskin & Harcourt, December 22, 2009: CA2276267

Peptide-lipid conjugates are incorporated into liposomes so as to selectively destabilize the liposomes in the vicinity of target peptidase-secreting cells, and hence, to deliver the liposomes to the vicinity of the target cells, or directly into the cells. The liposomes can thus be used to treat ma ...


9

10
Sugimoto Masanobu, Arella Max, Furuichi Yasuhiro: Lipid-based artificial particles inducing cell-mediated immunity. Sapientia Therapeutics, Agene Research Institute, Sugimoto Masanobu, Arella Max, Furuichi Yasuhiro, ROBIC, October 5, 2000: WO/2000/057919

Artificial immunogenic particles (1), methods for producing the same and uses thereof are disclosed. The immunogenic particles (1) of the invention comprise a lipid-based matrix (3), glycolipids (5, 6) and peptide-lipid conjugates (7, 8) embedded into this matrix (3). These particles (1) are highly ...